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Pseudomonas aeruginosa infection is a hallmark of lung disease in cystic ﬁbrosis. Acute infection with P. aeruginosa profoundly inhibits
alveolar macrophage clearance of apoptotic cells (efferocytosis) via direct effect of virulence factors. During chronic infection, P. aeruginosa
evades host defense by decreased virulence, which includes the production or, in the case of mucoidy, overproduction of alginate. The impact of
alginate on innate immunity, in particular on macrophage clearance of apoptotic cells is not known.
We hypothesized that P. aeruginosa strains that exhibit reduced virulence impair macrophage clearance of apoptotic cells and we investigated if
the polysaccharide alginate produced by mucoid P. aeruginosa is sufﬁcient to inhibit alveolar macrophage efferocytosis.
Rat alveolar or human peripheral blood monocyte (THP-1)-derived macrophage cell lines were exposed in vitro to exogenous alginate or to
wild type or alginate-overproducing mucoid P. aeruginosa prior to challenge with apoptotic human Jurkat T-lymphocytes. The importance of LPS
contamination and that of structural integrity of alginate polymers was tested using alginate of different purities and alginate lyase, respectively.
Alginate inhibited alveolar macrophage efferocytosis in a dose- and time-dependent manner. This effect was augmented but not exclusively
attributed to lipopolysaccharide (LPS) present in alginates. Alginate-producing P. aeruginosa inhibited macrophage efferocytosis by more than
50%. A mannuronic-speciﬁc alginate lyase did not restore efferocytosis inhibited by exogenous guluronic-rich marine alginate, but had a marked
beneﬁcial effect on efferocytosis of alveolar macrophages exposed to mucoid P. aeruginosa.
Despite decreased virulence, mucoid P. aeruginosa may contribute to chronic airway inﬂammation through signiﬁcant inhibition of alveolar
clearance of apoptotic cells and debris. The mechanism by which mucoid bacteria inhibit efferocytosis may involve alginate production and
synergy with LPS, suggesting that alginate lyase may be an attractive therapeutic approach to airway inﬂammation in cystic ﬁbrosis and other
chronic obstructive pulmonary diseases characterized by P. aeruginosa colonization.
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Cystic fibrosis (CF) is the most common autosomal recessive
disorder with an estimated incidence of 1 in 3000 Caucasians [1].
Themajority of individuals with CF have positive sputum cultures
for Pseudomonas aeruginosa. Infection with P. aeruginosa
is associated with significant morbidity and mortality [2,3].ll rights reserved.
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P. aeruginosa infection via phagocytosis of bacteria, which is
followed by neutrophil apoptosis. In turn, apoptotic cell clearance
(efferocytosis) from the airways by alveolar macrophages (AMs)
is an essential step in the resolution of inflammation [4,5].
It has been established that acute infectious (planktonic)
P. aeruginosa increases PMN apoptosis but decreases their
clearance by AM via mechanisms involving pyocyanin and Type
III Secretion System (T3SS) production, a classical virulence
factor [6,7]. This mechanism may be partly responsible for
chronic PMN infiltration of CF airways, increased mucous
viscosity, and perpetuation of airway inflammation. However,
with the transition to chronicity, microbes accumulate mutations
rendering CF airways frequently colonized by P. aeruginosa
strains with lower virulence [8–10]. These strains associated with
chronic airway infections produce more biofilms and
down-regulate T3SS and pyocyanin production, attempting to
evade host immunity [11]. Despite this decrease in expression of
classical virulence factors, mucoid P. aeruginosa, an alginate
overproducing mutant [12] often found in CF sputum cultures, is
associated with higher morbidity and mortality in persons with
CF [13]. The alginate-containing biofilm produced by the mucoid
strain has been shown to impair antibiotic penetration and to
inhibit phagocytosis of bacteria, whereas treatment with alginate
lyase improves antibiotic responses and sputum viscosity
[14–16]. However, bacterial and apoptotic cell phagocytoses do
not share similar mechanisms. The effect of alginate on AM
efferocytosis is unknown, but such an effect could play an
essential role in airway inflammation and therefore the morbidity
of chronic P. aeruginosa infection. Accordingly, restoration of
inflammatory clearance by means of mitigating alginate produc-
tion or breaking down its polymers with alginate lyase might
provide the rationale for potential therapeutic interventions,
especially in the setting of increased antibiotic resistance.
We hypothesize that alginate produced by less virulent, mucoid
P. aeruginosa will decrease AM efferocytosis and that alginate
lyase treatment will improve AM engulfment of apoptotic cells in
the presence of mucoid bacteria.
2. Materials and methods
2.1. Reagents
All reagents were from Sigma-Aldrich (St. Louis, MO), unless
otherwise specified. LPS, from Escherichia coli strain O111:
B4 was from Thermo Scientific (Asheville, NC).
2.2. Cells
Rat alveolar macrophage (AM) cell line NR8383 (ATCC,
Manassas, VA) was maintained in Ham's F12Kmedium (ATCC)
containing L-glutamine (2 mM), sodium bicarbonate (1.5 g/L),
and heat-inactivated fetal bovine serum (FBS, 15%). Select
experiments (as noted) were performed with monocyte derived
macrophages from human THP-1 line (ATCC) differentiated
with phorbol 12-myristate 13-acetate (PMA; 5 nM, 48 h).
Human acute T cell leukemia cell line Jurkat (ATCC) wasmaintained in RPMI-1640 supplemented with heat-inactivated
FBS (10%), penicillin (100 U/ml), and streptomycin (0.1 mg/ml).
All cells were maintained in an incubator at 37 °C, 5% CO2.
2.3. Treatments
Cells were treated with sodium alginate (Spectrum Chemical,
New Brunswick, NJ) at 0.2 mg/ml, 0.5 mg/ml, 1.0 mg/ml, or
2.5 mg/ml or its vehicle (sterile water) for 0, 4, or 24 h in F12K
media with 2% FBS at 37 °C, 5% CO2. These alginate con-
centrations are within ranges used in studies investigating
alginate interactions with P. aeruginosa [17], as well as similar
to alginate levels produced by certain mucoid P. aeruginosa
strains [18,19]. After treatment, AM were either immediately
used, or were first rinsed in PBS and then used, or were rinsed and
then recovered for 24 h in full culture media and then used in
efferocytosis experiments, as indicated. Alginate preparations are
often contaminated with LPS due to processing conditions. Thus,
to investigate the role of LPS contamination, alginate was
assayed using a Limulus Amebocyte Lysate (LAL) based kit
(Thermo Scientific) and compared to other alginate preparations
(Pronova–Nova Matrix, Ewing, NJ), which were ultra-purified
(LPS-free), as noted.
2.4. Efferocytosis
Apoptotic targets were obtained from Jurkat cells labeled with
Cell Tracker Orange (Invitrogen, Grand Island, NY; 0.5 mM)
and exposed to UV radiation (30,000 μJ/cm2) using a HL-2000
HybriLinker, followed by incubation for 3.5 h at 37 °C, 5% CO2
in serum-free media. Apoptotic Jurkat cells were co-cultured (1 h
at 37 °C) with AM in a 5:1 ratio. Afterwards, cells were collected
and extracellular fluorescence (of membrane-bound but non-
engulfed apoptotic cells or bodies) was quenched with trypan
blue (Sigma; 500 μl; 0.04% in PBS) [20]. Cells were then fixed
with 1% paraformaldehyde. Efferocytosis was evaluated by
flow cytometry using Cytomics FC500 cytofluorimeter with
CXP software (Beckman Coulter, Fullerton, CA), as described
(Fig. 1A) [20].
2.5. Bacteria
The strains ofP. aeruginosa used were PA14 (a highly virulent
human clinical isolate) [21], PA01 (the standard laboratory
reference strain) [22], and FRD1 (a mucoid strain isolated from
a CF patient) [23]. The following mutants were used: isogenic
deletion mutant for the genes phzM and exsA in PA14 (PAKO),
which lacks pyocyanin and T3SS, an algD mutant in PA01 to
eliminate alginate production [24,25]. Isogenic deletions in phzM
and exsA were created using an allelic replacement technique, as
previously described [24]. For phzM mutation, we used the
primers PhzMLfor (5′ TCG ACT GAG CCT TTC GTT TTA
TTT GAT GCC TGG CAG TTC CGA TCC TCG GTC TCG
AAG ATC 3′), PhzMLrev (5′ CAG CCG TTG AGA GTT CCG
GTC TCT CGT TAC ACA TTT CCG T 3′), PhzMRfor (5′ ACG
GAA ATG TGT AAC GAG AGA CCG GAA CTC TCA ACG
GCTG 3′), and PhzMRrev (5′GGAATT GTGAGCGGA TAA
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Fig. 2. Impact of lipopolysaccharide (LPS) in alginate on efferocytosis.
Efferocytosis index of alveolar macrophages (NR8383) following exposure to
alginate (2.5 mg/ml; 4 h; 0.25 EU LPS/ml of media) compared to alginate
preparations with low LPS contamination (final concentrations of LPS in media
as indicated), or to LPS alone (1 EU/ml). Mean + SEM; (mean + SEM of
control, 53.17 + 7.31); n = 3; ANOVA, p b 0.0001; Tukey's post-hoc,
*p b 0.0001, #p b 0.005, and $p b 0.01.
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GAC CTG TTC 3′). Deletions were confirmed by PCR using
primers PhzMfor (5′GTTGTTTCCGCAACGAGATC 3′) and
PhzMrev (5′ GCA ACG CGC TCA ACC AAC TG 3′). Deletion
of exsA was described previously [25]. The algD mutant was
kindly donated by Dr. George O'Toole, Geisel School of
Medicine at Dartmouth. Bacteria were grown overnight in liquid
LB media and then working suspensions were prepared to an
OD600 of 0.6, as measured by spectrometry. These bacterial
suspensions and apoptotic cells were co-cultured with macro-
phages for 1 h. Where indicated, alginate lyase was added to
bacterial suspensions alone for 4 h before efferocytosis
experiments.
2.6. Alginate lyase activity
Alginate lyase was obtained from Sphingobacterium
multivorum (Sigma-Aldrich), and has specificity for cleaving
mannuronic acid bonds. The reaction was initiated by adding
alginate lyase (in PBS, pH 7.4) to alginate (1:30 vol:vol). The
enzyme activity (4 h at 37 °C) was measured with a SpectraMax
M2 plate reader (Molecular Devices Inc., Sunnyvale, CA) at
235 nm.
Cellular toxicity was determined using an in vitro MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
assay, according to the manufacturer's (Sigma) protocol.
The absorbance of formazan was measured at 570 nm with a
SpectraMax M2 plate reader.
2.7. Statistical methods
Differences among groups were assessed using either t-test
for two groups or ANOVA for 3 or more groups with post-hoc
Tukey's testing for significant differences between selected
groups. Statistical difference was considered significant when
p is b0.05. Analyses were performed using Prism Software
(GraphPad Software, Inc., La Jolla, CA).
3. Results
3.1. Effect of alginate on AM efferocytosis
We first determined if alginate, a complex copolymer present in
the biofilm formed by P. aeruginosa during chronic infections, is
sufficient to impair AM efferocytosis. We exposed rat AM
(NR8383 cell line) to exogenous sodium alginate suspensions ofFig. 1. Effect of sodium alginate on efferocytosis. (A) Schematic of efferocytosis flo
and set for negative fluorescence (autofluorescence) on FSC/FL2 panel (gate AJ). Wh
can be seen as a population of larger and more complex events in panel FSC/SSC
fluorescent targets) in panel FSC/FL2. The quenching with trypan blue discriminate
apoptotic Jurkat cells by rat alveolar macrophages (NR8383 cell line) in the presence o
Efferocytosis was expressed as relative phagocytic index (% of vehicle control; mean
Tukey's post-hoc, *p ≤ 0.0001 and #p ≤ 0.01); (C) (mean + SEM of control, 35.55
index of rat alveolar macrophages (NR8383) following exposure to alginate (2.5 m
(present), immediately following removal of alginate (rinsed), or 24 h following remov
ANOVA, p ≤ .0001; Tukey's post-hoc, #p ≤ b0.0001, $p b 0.01, and *p b 0.05. (E
conditions: untreated, vehicle treated (water) and alginate (2.5 mg/ml) treated for 4 hvarying concentrations (Fig. 1B) and for varying time (Fig. 1C),
followed by AM co-culture with apoptotic targets. Alginate
inhibited efferocytosis of apoptotic targets (fluorescently-labeled
UV-irradiated Jurkat T-cells) in a dose- and time- dependent
fashion, as measured by flow cytometry. The highest dose of
alginate tested (2.5 mg/ml) exerted an inhibitory effect on AM
efferocytosis after as early as 5 min of treatment, and was most
profound after 24 h of incubation.
To determine the persistence of efferocytosis impairment
following treatment with sodium alginate, rat AM efferocytosis
was investigated following the removal of alginate. After alginate
treatment, cells were either rinsed and immediately co-cultured
with apoptotic targets, or were rinsed and allowed to recover in
fresh media for 24 h prior to co-culture with apoptotic targets
(Fig. 1D). The immediate removal of alginate from the co-culture
did not significantly change the inhibitory impact on AM
efferocytosis. Interestingly, cells that were allowed to recover
overnight exhibited only partial (20%) restoration of their
efferocytosis potential compared with cells from which alginate
was not rinsed, and only a non-significant (9%, p = 0.4) recovery
of efferocytosis compared to cells that were tested immediately
after alginate was rinsed. Given the persistence of the effect of
alginate on efferocytosis, to rule out a nonspecific toxic effect, we
tested if alginate (2.5 mg/ml) altered macrophage viability, asw-cytometry method. Macrophage population was gated on FSC/SSC (gate B)
en assessing the engulfment, the macrophages which engulfed apoptotic targets
(black) which were then evaluated (and measured as % cells which engulfed
d engulfed from potentially attached apoptotic targets. (B–D) Efferocytosis of
f alginate at the indicated concentrations (B, 24 h) and time points (C, 2.5 mg/ml).
+ SEM; n = 3; (mean + SEM of control, 47.35 + 2.49); B: ANOVA, p ≤ .0001;
+ 2.55); ANOVA, p ≤ .0001; Tukey's post-hoc, *p ≤ 0.0001. (D) Efferocytosis
g/ml; 4 h). Engulfment was assessed in co-cultures in the presence of alginate
al of alginate (rinsed & recovered). (Mean + SEM of control, 29.9 + 3.24); n = 3;
–F) Metabolic activity measured by MTT assay in macrophages in the following
and 24 h, respectively (mean + SEM, n = 3).
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alginate did not exhibit decreased metabolic activity. These
results suggest that alginate is a potent inhibitor of alveolar
macrophage efferocytosis and this effect is not solely due to its
physical presence in co-cultures or to a non-specific toxic effect
on AM.
3.2. Effects of LPS on AM efferocytosis
Since purified alginate may be contaminated with varying
amounts of lipopolysaccharide (LPS) [26], we investigated
the levels and potential contribution of LPS contamination of
alginate on efferocytosis. The alginate used in the experiments
above was tested using the limulus amebocyte assay and found
to contain 100 EU LPS/g of alginate, which is considered a low
level of contamination [26]. We then compared the effect
of this alginate (1 EU LPS/ml alginate) with that of highly
purified alginates (0.3 and 0.4 EU LPS/ml alginate, respective-
ly) on efferocytosis. We noted that alginate containing lower
levels of LPS had less inhibitory effect on efferocytosis (Fig. 2),
suggesting a contributory effect of LPS on alginate-induced
AM dysfunction. However, comparable exposures (4 h) to LPS
alone without alginate, in concentrations even higher than those
found in alginate did not inhibit AM efferocytosis (Fig. 2).
These results suggest a cooperative effect of LPS and alginate
on macrophage engulfment of apoptotic cells.
3.3. Effects of P. aeruginosa on AM efferocytosis
We investigated if alginate-producing (mucoid) strains of
P. aeruginosa, typically present in the biofilm of CF chronic
airway infection, inhibit efferocytosis. We studied the effect of
a mutant P. aeruginosa lacking the pyocyanin and T3SS toxins
(PAKO) relative to the wild-type (PA14) P. aeruginosa strain,
which is known to inhibit efferocytosis via production of toxins
such as pyocyanin [7]. The toxin-deficient strain significantly
inhibited efferocytosis by more than 50% (Fig. 3). This inhibitoryFig. 3. Efferocytosis of alveolar macrophages exposed to P. aeruginosa strains.
Efferocytosis index of rat alveolar macrophages (NR8383) during exposure to
the following strains of P. aeruginosa: wild type (WT; non-mucoid; PA14),
mutated (virulence-attenuated PAKO), or mucoid (alginate overproducer;
FRD1). The ratio of bacteria: macrophages: apoptotic cells during co-culture
was 1:5:5. Mean + SEM; (mean + SEM of control, 50.13 + 4.8); n = 3;
ANOVA, p b 0.0001; Tukey's post-hoc, *p b 0.0001; #p b 0.01.effect was less potent compared to wild type bacteria which
depressed efferocytosis by 70%, but it was remarkably similar to
the effect of alginate alone. As a comparison, we also tested a
CF-adapted, mucoid strain (FRD1). Importantly, this mucoid
strain also inhibited efferocytosis by more than 50% (Fig. 3).
3.4. Impact of alginate lyase (AL) treatment on efferocytosis
We tested if the breakdown of high-molecular weight alginate
polymers with AL will prevent its inhibitory effect on
efferocytosis. After testing the activity of purified AL at neutral
pH (Fig. 4A), we incubated AL with exogenous alginate prior to
exposure of AM. Whereas AL treatment did not affect the
inhibitory effect of alginate on AM efferocytosis (Fig. 4B), it
significantly attenuated the effect of mucoid, alginate producing
(FRD1) P. aeruginosa on efferocytosis (Fig. 4C). However, AL
had no impact on efferocytosis inhibition in response to wild type
P. aeruginosa or an alginate non-producer mutant strain (data
not shown). These data suggest that alginate is in large part
responsible for the efferocytosis inhibitory effect of mucoid
P. aeruginosa.
4. Discussion
Whereas the pathogenic effects of P. aeruginosa during acute
infections are attributed in large part to toxin production, the
production of virulent toxins is markedly decreased during
chronic bacterial persistence in biofilm [27,28]. Even though the
low virulence of P. aeruginosa in biofilm infections accounts for
decreased anti-bacterial host responses, it is becoming increas-
ingly evident that biofilm-state P. aeruginosa continues to exert
pathogenic effects on the airways. The main finding of this report
is that even P. aeruginosa with low virulence inhibits the clear-
ance of apoptotic cells by macrophages, a critical innate host
defense mechanism. We further report that this pathogenic effect
may be due to a synergistic effect of alginate and LPS.
Similar to findings of Bianchi et al., our data indicate that wild
type, pyocyanin-producing virulent P. aeruginosa has profound
inhibitory effect on efferocytosis [7]. In addition, we show
that even bacteria that lack these virulence factors can inhibit
efferocytosis, albeit to a lesser degree. The dose-dependent effect
of alginate on efferocytosis implicates this complex copolymer as
one of the mediators by which mucoid P. aeruginosa inhibits
macrophage engulfment of apoptotic cells. Of the three
exopolymers secreted by mucoid P. aeruginosa Pel, Psl, and
alginate, only the latter is found in bacteria adapted to the CF lung
[29]. Alginate has been involved in other effects of mucoid
P. aeruginosa on the innate immunity, such as decreased
phagocytosis of bacteria by PMN, in addition to decreasing
local antibiotic penetration, or, at higher concentrations, modu-
lating the T3SS of the bacteria [17]. Secreted in abundance by
mucoid P. aeruginosa, alginate is an unbranched polysaccharide
composed of monomers of L-guluronic acid and D-mannuronic
acid [30]. While pure alginate does not contain LPS, the steps
necessary to purify alginate from various sources are associated
with varied degrees of contamination of alginate with LPS. For
example, alginate purified from cultured mucoid bacteria is
Fig. 4. Effect of alginate lyase (AL) on efferocytosis inhibition by alginate and alginate-producing P. aeruginosa. (A) AL activity (mU/min; pH 7.4) measured during
incubation of purified AL (1 U/ml) with its substrate alginate (Alg, 2.5 mg/ml), compared to controls such as vehicle (Veh), alginate alone, or AL in the absence of
substrate. Mean + SEM; n = 3. (B) Effect of pre-incubation of AL with alginate (at the indicated concentrations; 1:30 v:v ratio AL:alginate; 45 min.) on efferocytosis
of alveolar macrophages (NR8383 cells) exposed to alginate (2.5 mg/ml; 4 h). Mean + SEM; (mean + SEM of control, 40.62 + 4.3); n = 6; t-test, *p b 0.05.
(C) Effect of pre-incubation of AL (1 U/ml; 4 h) with mucoid P. aeruginosa (alginate overproducer; FRD1) on efferocytosis of human peripheral blood monocyte
(THP-1)-derived macrophages. The ratio of bacteria: macrophages:apoptotic cells was 2.5:1:5. Mean + SEM; (mean + SEM of control, 48.19 + 5.03); n = 3;
ANOVA, p b 0.0001; Tukey's post-hoc, *p b 0.01, #p b 0.05.
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The commercial alginate preparation purified from algae used in
our study contained 4-fold less LPS than alginate typically
purified from bacteria. Although bacterial LPS alone at similar
concentrations did not inhibit macrophage efferocytosis, we
demonstrated a cooperative effect of LPS with alginate to inhibit
efferocytosis. Whether this phenomenon could be explained by
common signaling pathways engaged by alginate and LPS, such
as TLR4 receptor activation, will need experimental confirmation
in future investigations. One cannot exclude the possibility that
other contaminants in the alginate extract, or other immunogenic
components of biofilm in addition to alginate, may impact
efferocytosis [32]. However, our results showing the effect of
alginate-producing P. aeruginosa, which was diminished by AL,
suggest alginate-specific inhibition of efferocytosis. Although not
directly compared in our model, our results also suggest that both
bacteria producing alginate and algae alginate have inhibitory
effects on efferocytosis, despite structural dissimilarities of the
two exopolymers. The mechanism by which alginate impairs
efferocytosis may include alteration of expression or accessibility
of efferocytosis-required receptors at the plasma membrane. Such
a candidate could be ABCA1, one of the twelve members of theABC transporter system that plays an important role in
efferocytosis [33], since alginate molecules interact via the ABC
system [34] and ABCA1 has been shown to be downregulated by
LPS [35].
It is interesting that the enzymatic breakdown of the copolymer
by incubation with AL did not rescue efferocytosis impaired by
marine alginate, whereas the enzyme was effective in rescuing
efferocytosis inhibited by alginate-overproducing bacteria. It is
possible that the effectiveness of the enzyme may be related to
reaction conditions in vitro or to substrate accessibility, given the
variability in monomer type predominance and acetylation of
different alginates [36]. In particular, the AL used in our
experiments has specificity for mannuronic acid. The fact that
guluronate is more prevalent in algal alginate and mannuronate
is more abundant in Pseudomonas alginate may explain why
AL was more effective in cleaving bacterial alginate. Although
AL may be inhibited by acetylation [37] and bacterial alginate
is heavily acetylated, treatment of alginate overproducing
P. aeruginosa strain FRD1 with AL led to significant increases
(and partial recovery) in efferocytosis and support the notion that
bacterial alginate, like algal alginate, contributes to the detrimental
effect of mucoid P. aeruginosa on this innate immune function.
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of macrophage function, due to the difficulty to establish chronic
mucoid P. aeruginosa airway infection or colonization in animals
[38]. Nevertheless, these results may be relevant to human lung
diseases characterized by airway colonization and chronic bio-
film infection with P. aeruginosa, such as CF, COPD,
and non-CF bronchiectasis. Chronic airway infection with
P. aeruginosa is known to decrease lung function and increased
mortality in CF and is characterized by production of a biofilm
containing the polysaccharide alginate and by decreased
microbial virulence, an attempt to evade host immunity. Indeed,
the biofilm matrix, composed of extracellular polysaccharides
such as alginate, Pel, and Psl [29], along with DNA, protein, and
other host components, protect the constituent bacteria from
immune attack and from antibiotic treatment [9]. Despite
decreased virulence, mucoid P. aeruginosa is still associated
with decline in lung function. We have shown that alginate
decreases the removal of dead cells by macrophages, which may
cause prolonged airway inflammation and lung dysfunction.
Since mucoid biofilm infections are characterized by marked
secretion of alginate [39,40], our data implicate mucoid P.
aeruginosa in airway inflammation, associated with alginate
inhibition of alveolar macrophage efferocytosis. The impairment
of lung macrophage efferocytosis contributes to airway inflam-
mation through mechanisms that include release of
pro-inflammatory mediators from non-engulfed apoptotic cells
(via secondary necrosis), increased mucus viscosity from spilled
DNA, and loss of anti-inflammatory phenotype of alveolar
macrophages associated with apoptotic cell engulfment. Several
studies suggest that airway inflammation further propagates
bacterial biofilm persistence. The released intracellular proteins
and nucleic acids, which increase airway mucus viscosity,
enhance the bacterial biofilm matrix that surrounds and protects
bacteria [41]. Biofilm polysaccharides themselves exert a positive
feedback on further biofilm synthesis [42]. In addition,
persistently activated immune cells, which may include macro-
phages with impaired efferocytosis, exert oxidative stress which
promotes P. aeruginosamutations (mucA) that stimulate alginate
overexpression [9,43]. These dysregulated host–microbe inter-
actions support that alginate lyase or other methods to mitigate
alginate accumulation in the airway may decrease airway
inflammation and biofilm formation in chronic P. aeruginosa
infection in CF and other bronchiectatic patients.
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